Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.…
Nautilus: 3 Key Takeaways for Long-Term Investors
Nautilus Biotechnology (NASDAQ: NAUT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 128 employees.
The shares were at 2.120 USD on 20 November 2026, up 27.7% over 52 weeks. Its 52-week range is 0.8411 USD to 4.310 USD: the price is 50.8% below the high and 152.1% above the low.
Its market capitalisation is 270.03M USD.
Nautilus Biotechnology reports return on equity of -37.6%.
It holds more cash than debt, a net cash position of 59.84M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 4.000 USD is 88.7% above the current price. The next earnings report is expected on 25 February 2027.